Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Bone ; 40(1): 122-31, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16962401

ABSTRACT

Cathepsin K is an osteoclast-derived cysteine protease that has been implicated as playing a major role in bone resorption. A substantial body of evidence indicates that cathepsin K is critical in osteoclast-mediated bone resorption and suggests that its pharmacological inhibition should result in inhibition of bone resorption in vivo. Here we report the pharmacological characterization of SB-462795 (relacatib) as a potent and orally bioavailable small molecule inhibitor of cathepsin K that inhibits bone resorption both in vitro in human tissue and in vivo in cynomolgus monkeys. SB-462795 is a potent inhibitor of human cathepsins K, L, and V (K(i, app)=41, 68, and 53 pM, respectively) that exhibits 39-300-fold selectivity over other cathepsins. SB-462795 inhibited endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of approximately 45 nM and approximately 70 nM, respectively. The anti-resorptive potential of SB-462795 was evaluated in normal as well as medically ovariectomized (Ovx) female cynomolgus monkeys. Serum levels of the C- and N-terminal telopeptides of Type I collagen (CTx and NTx, respectively) and urinary levels of NTx were monitored as biomarkers of bone resorption. Administration of SB-462795 to medically ovariectomized or normal monkeys resulted in an acute reduction in both serum and urinary markers of bone resorption within 1.5 h after dosing, and this effect lasted up to 48 h depending on the dose administered. Our data indicate that SB-462795 potently inhibits human cathepsin K in osteoclasts, resulting in a rapid inhibition of bone resorption both in vitro and in vivo in the monkey. These studies also demonstrate the therapeutic potential of relacatib in the treatment of postmenopausal osteoporosis and serves to model the planned clinical trials in human subjects.


Subject(s)
Azepines/therapeutic use , Bone Resorption/drug therapy , Cathepsins/antagonists & inhibitors , Osteoclasts/drug effects , Sulfones/therapeutic use , Administration, Oral , Animals , Azepines/administration & dosage , Azepines/pharmacology , Biomarkers/blood , Biomarkers/urine , Cathepsin K , Cells, Cultured , Collagen Type I/blood , Collagen Type I/urine , Disease Models, Animal , Humans , Macaca fascicularis , Osteoclasts/enzymology , Peptides/blood , Peptides/urine , Sulfones/administration & dosage , Sulfones/pharmacology
2.
J Pept Res ; 63(3): 265-9, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15049838

ABSTRACT

The design, synthesis, enzymologic, and protein mass spectrometric characterization of benzodioxocin-3-one and N-acyl-3-amino-3-buten-2-one inhibitors of the cysteine protease cathepsin K are described. The benzodioxocin-3-one ring system is chemically unstable giving rise to a mixture of N-acyl-3-amino-3-buten-2-one and hemiketals. This mixture of N-acyl-3-amino-3-buten-2-one and hemiketals potently inhibits recombinant, human cathepsin K (IC50 = 36 nM) by a time-independent, irreversible mechanism. Formation of a covalent adduct between cathepsin K and inhibitor has been confirmed by mass spectrometry.


Subject(s)
Cathepsins/antagonists & inhibitors , Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Ketones/chemistry , Ketones/pharmacology , Cathepsin K , Cathepsins/chemistry , Cysteine Endopeptidases/metabolism , Cysteine Proteinase Inhibitors/chemical synthesis , Cysteine Proteinase Inhibitors/classification , Ketones/chemical synthesis , Molecular Structure
3.
J Med Chem ; 44(9): 1380-95, 2001 Apr 26.
Article in English | MEDLINE | ID: mdl-11311061

ABSTRACT

The synthesis, in vitro activities, and pharmacokinetics of a series of azepanone-based inhibitors of the cysteine protease cathepsin K (EC 3.4.22.38) are described. These compounds show improved configurational stability of the C-4 diastereomeric center relative to the previously published five- and six-membered ring ketone-based inhibitor series. Studies in this series have led to the identification of 20, a potent, selective inhibitor of human cathepsin K (K(i) = 0.16 nM) as well as 24, a potent inhibitor of both human (K(i) = 0.0048 nM) and rat (K(i,app) = 4.8 nM) cathepsin K. Small-molecule X-ray crystallographic analysis of 20 established the C-4 S stereochemistry as being critical for potent inhibition and that unbound 20 adopted the expected equatorial conformation for the C-4 substituent. Molecular modeling studies predicted the higher energy axial orientation at C-4 of 20 when bound within the active site of cathepsin K, a feature subsequently confirmed by X-ray crystallography. Pharmacokinetic studies in the rat show 20 to be 42% orally bioavailable. Comparison of the transport of the cyclic and acyclic analogues through CaCo-2 cells suggests that oral bioavailability of the acyclic derivatives is limited by a P-glycoprotein-mediated efflux mechanism. It is concluded that the introduction of a conformational constraint has served the dual purpose of increasing inhibitor potency by locking in a bioactive conformation as well as locking out available conformations which may serve as substrates for enzyme systems that limit oral bioavailability.


Subject(s)
Azepines/chemical synthesis , Cathepsins/antagonists & inhibitors , Enzyme Inhibitors/chemical synthesis , Leucine/chemical synthesis , Administration, Oral , Animals , Azepines/chemistry , Azepines/pharmacokinetics , Azepines/pharmacology , Biological Availability , Cathepsin K , Chromatography, High Pressure Liquid , Crystallography, X-Ray , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacokinetics , Enzyme Inhibitors/pharmacology , Humans , In Vitro Techniques , Leucine/analogs & derivatives , Leucine/chemistry , Leucine/pharmacokinetics , Leucine/pharmacology , Mass Spectrometry , Models, Molecular , Molecular Structure , Osteoclasts/drug effects , Protein Binding , Rats , Stereoisomerism , Structure-Activity Relationship
4.
J Biol Chem ; 276(15): 11507-11, 2001 Apr 13.
Article in English | MEDLINE | ID: mdl-11148212

ABSTRACT

Cathepsins K and L are related cysteine proteases that have been proposed to play important roles in osteoclast-mediated bone resorption. To further examine the putative role of cathepsin L in bone resorption, we have evaluated selective and potent inhibitors of human cathepsin L and cathepsin K in an in vitro assay of human osteoclastic resorption and an in situ assay of osteoclast cathepsin activity. The potent selective cathepsin L inhibitors (K(i) = 0.0099, 0.034, and 0.27 nm) were inactive in both the in situ cytochemical assay (IC(50) > 1 micrometer) and the osteoclast-mediated bone resorption assay (IC(50) > 300 nm). Conversely, the cathepsin K selective inhibitor was potently active in both the cytochemical (IC(50) = 63 nm) and resorption (IC(50) = 71 nm) assays. A recently reported dipeptide aldehyde with activity against cathepsins L (K(i) = 0.052 nm) and K (K(i) = 1.57 nm) was also active in both assays (IC(50) = 110 and 115 nm, respectively) These data confirm that cathepsin K and not cathepsin L is the major protease responsible for human osteoclastic bone resorption.


Subject(s)
Bone Resorption , Cathepsins/antagonists & inhibitors , Cysteine Proteinase Inhibitors/pharmacology , Endopeptidases , Osteoclasts/drug effects , Cathepsin L , Cysteine Endopeptidases , Humans , Osteoclasts/cytology , Tumor Cells, Cultured
5.
Curr Pharm Des ; 6(1): 1-24, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10637370

ABSTRACT

Cathepsin K, a cysteine protease of the papain family, was identified by sequencing complementary DNA libraries derived from osteoclasts. Cathepsin K can cleave bone proteins such as Type I collagen, osteopontin, and osteonectin. The localization and maturation of cathepsin K in activated osteoclasts have been characterized. Furthermore, mutation of the gene expressing cathepsin K in humans results in pycnodysostosis, an autosomal recessive condition, resulting in osteoprosis and increased bone fragility. Knockout of cathepsin K in the mouse also results in retarded bone matrix degradation and osteopetrosis. Together, these data demonstrate that inhibition of cathepsin K should result in a dimunition of osteoclast-mediated bone resorption. Several novel classes of cathepsin K inhibitors have been designed from X-ray co-crystal structures of peptide aldehydes bound to papain. The convergence of the design of novel inhibitors and the discovery of cathepsin K has created opportunities to further understand bone and cartilage biology as well as provide new therapeutic agents for the treatment of disease states in man such as osteoporosis.


Subject(s)
Cathepsins/antagonists & inhibitors , Cathepsins/physiology , Cysteine Proteinase Inhibitors/chemical synthesis , Cysteine Proteinase Inhibitors/pharmacology , Animals , Cathepsin K , Cathepsins/genetics , Cathepsins/metabolism , Drug Design , Humans , Structure-Activity Relationship
6.
Bioorg Med Chem ; 7(4): 581-8, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10353637

ABSTRACT

Cathepsin K (EC 3.4.22.38) is a cysteine protease of the papain superfamily which is selectively expressed within the osteoclast. Several lines of evidence have pointed to the fact that this protease may play an important role in the degradation of the bone matrix. Potent and selective inhibitors of cathepsin K could be important therapeutic agents for the control of excessive bone resorption. Recently a series of peptide aldehydes have been shown to be potent inhibitors of cathepsin K. In an effort to design more selective and metabolically stable inhibitors of cathepsin K, a series of electronically attenuated alkoxymethylketones and thiomethylketones inhibitors have been synthesized. The X-ray co-crystal structure of one of these analogues in complex with cathepsin K shows the inhibitor binding in the primed side of the enzyme active site with a covalent interaction between the active site cysteine 25 and the carbonyl carbon of the inhibitor.


Subject(s)
Cathepsins/antagonists & inhibitors , Cysteine Proteinase Inhibitors/chemical synthesis , Endopeptidases , Ketones/chemistry , Cathepsin B/antagonists & inhibitors , Cathepsin K , Cathepsin L , Cysteine Endopeptidases , Kinetics , Models, Chemical , Models, Molecular
7.
J Comb Chem ; 1(3): 207-15, 1999.
Article in English | MEDLINE | ID: mdl-10746010

ABSTRACT

To more rapidly prepare members of the 1,3-bis(acylamino)-2-butanone class of cysteine protease inhibitors, a solid-phase synthesis was developed. 1-Azido-3-amino-2,2-dimethoxybutane (4), which has the two amino groups differentiated and the ketone protected as a a ketal, served as a surrogate for the 1,3-diamino-2-butanone core. Amine (4) was coupled to the BAL-resin-linked carboxylic acids derived from alpha-amino acid esters. Evaluation of a small combinatorial array by measuring inhibition constants (Ki,appS) against cathepsins K, L, and B provided some structure-activity relationship trends with respect to selectivity and potency. Novel, potent inhibitors of cathepsins K and L were identified.


Subject(s)
Butanones/chemical synthesis , Cathepsins/antagonists & inhibitors , Combinatorial Chemistry Techniques/methods , Cysteine Proteinase Inhibitors/chemical synthesis , Endopeptidases , Butanones/chemistry , Butanones/pharmacology , Cathepsin K , Cathepsin L , Cysteine Endopeptidases , Cysteine Proteinase Inhibitors/chemistry , Cysteine Proteinase Inhibitors/pharmacology , Drug Design , Kinetics , Models, Molecular , Structure-Activity Relationship
8.
J Med Chem ; 41(23): 4567-76, 1998 Nov 05.
Article in English | MEDLINE | ID: mdl-9804696

ABSTRACT

Papain has been used as a surrogate enzyme in a drug design effort to obtain potent and selective inhibitors of cathepsin K, a new member of the papain superfamily of cysteine proteases that is selectively and highly expressed in osteoclasts and is implicated in bone resorption. Here we report the crystal structures of two papain-inhibitor complexes and the rational design of novel cathepsin K inhibitors. Unlike previously known crystal structures of papain-inhibitor complexes, our papain structures show ligand binding extending deep within the S'-subsites. The two inhibitor complexes, carbobenzyloxyleucinyl-leucinyl-leucinal and carbobenzyloxy-L-leucinyl-L-leucinyl methoxymethyl ketone, were refined to 2.2- and 2.5-A resolution with R-factors of 0.190 and 0. 217, respectively. The S'-subsite interactions with the inhibitors are dominated by an aromatic-aromatic stacking and an oxygen-aromatic ring edge interaction. The knowledge of S'-subsite interactions led to a design strategy for an inhibitor spanning both subsites and yielded a novel, symmetric inhibitor selective for cathepsin K. Simultaneous exploitation of both S- and S'-sites provides a general strategy for the design of cysteine protease inhibitors having high specificity to their target enzymes.


Subject(s)
Cathepsins/antagonists & inhibitors , Cysteine Proteinase Inhibitors/chemistry , Dipeptides/chemistry , Leupeptins/chemistry , Models, Molecular , Papain/chemistry , Binding Sites , Cathepsin K , Crystallography, X-Ray , Cysteine Proteinase Inhibitors/metabolism , Dipeptides/metabolism , Drug Design , Leupeptins/metabolism , Papain/metabolism , Protein Structure, Tertiary
10.
Bioorg Med Chem ; 4(9): 1481-5, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8894105

ABSTRACT

Steroidal 3-carboxy-20-ketones have been prepared within two structural series, the androsta-3,5-dienes and the estra-1,3,5-trienes, as potential inhibitors of types 1 and 2 steroid 5 alpha-reductase, the enzyme activity responsible for the final step in biosynthesis of dihydrotestosterone. These compounds are shown to be potent uncompetitive inhibitors of both human recombinant enzyme activities, defining a novel class of dual steroid 5 alpha-reductase inhibitors.


Subject(s)
5-alpha Reductase Inhibitors , Androstadienes/chemistry , Enzyme Inhibitors/chemistry , Estrenes/chemistry , Keto Acids/chemistry , Chemical Phenomena , Chemistry , Humans , Hydrogen-Ion Concentration , Ketones/chemistry
11.
Chem Biol ; 2(7): 471-81, 1995 Jul.
Article in English | MEDLINE | ID: mdl-9383449

ABSTRACT

BACKGROUND: Rapamycin is an immunosuppressant natural product, which blocks T-cell mitogenesis and yeast proliferation. In the cytoplasm, rapamycin binds to the immunophilin FKBP12 and the complex of these two molecules binds to a recently discovered protein, FRAP. The rapamycin molecule has two functional domains, defined by their interaction with FKBP12 (binding domain) or with FRAP (effector domain). We previously showed that the allylic methoxy group at C-7 of rapamycin could be replaced by a variety of different substituents. We set out to examine the effects of such substitutions on FKBP12 binding and on biological activity. RESULTS: Rapamycin C-7-modified analogs of both R and S configurations were shown to have high affinities for FKBP12, yet these congeners displayed a wide range of potencies in splenocyte and yeast proliferation assays. The X-ray crystal structures of four rapamycin analogs in complexes with FKBP12 were determined and revealed that protein and ligand backbone conformations were essentially the same as those observed for the parent rapamycin-FKBP12 complex and that the C-7 group remained exposed to solvent. We then prepared a rapamycin analog with a photoreactive functionality as part of the C-7 substituent. This compound specifically labeled, in an FKBP12-dependent manner, a protein of approximately 250 kDa, which comigrates with recombinant FRAP. CONCLUSIONS: We conclude that the C-7 methoxy group of rapamycin is part of the effector domain. In the ternary complex, this group is situated in close proximity to FRAP, at the interface between FRAP and FKBP12.


Subject(s)
Carrier Proteins/metabolism , DNA-Binding Proteins/metabolism , Heat-Shock Proteins/metabolism , Immunophilins , Immunosuppressive Agents/pharmacology , Phosphotransferases (Alcohol Group Acceptor) , Polyenes/pharmacology , Animals , Blotting, Western , Carrier Proteins/chemistry , Carrier Proteins/drug effects , Cell Division/physiology , Crystallography, X-Ray , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/drug effects , Electrophoresis, Polyacrylamide Gel , Female , Heat-Shock Proteins/chemistry , Heat-Shock Proteins/drug effects , Immunosuppressive Agents/chemistry , Mice , Models, Molecular , Molecular Conformation , Photoaffinity Labels , Polyenes/chemistry , Protein Binding , Sirolimus , Spleen/cytology , Spleen/drug effects , Structure-Activity Relationship , TOR Serine-Threonine Kinases , Tacrolimus Binding Proteins , Yeasts/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...